Cookie Policy

Silence Therapeutics website uses cookies. By continuing to browse you are agreeing to our use of cookies.

Privacy and cookie notice
Menu
Silence-Logo-FINAL-rgb.png (1) logo-footer.png
Contact
  • About us

    Channelling gene silencing to control disease.

    Executive Leadership Team

    Our executive leadership team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to pharmaceutical development, BD deals and corporate finance.

    Strategy

    Our vision is to transform peoples' lives around the world by silencing diseases through our precision engineered medicines and driving positive change for the communities around us.

    Corporate Responsibility

    Silence Therapeutics strives to conduct its business in an ethical, responsible and transparent manner.

    Board of Directors

    Our Board of Directors is formed by seven accomplished members, two Executive and five Non-Executive Directors.

    Scientific Advisory Board

    We aim to stay in the frontline of the fast-moving field of oligonucleotide therapeutics. Our Scientific Advisory Board (SAB) is a group of world-leading experts in drug discovery and clinical development with particular expertise in the rare disease space. The SAB challenges us to excel at siRNA molecular design, drug discovery, and development

    Careers

    We offer a vibrant culture and environment where innovation and creativity are encouraged.

    Downloads

    July 2020 corp pres pic.JPG
    • Silence Therapeutics Corporate Presentation

    Download the Corporate Presentation here

  • Our Technology

    Our technology is a highly specific and modular platform designed to inhibit or ‘silence’ the expression of disease-causing genes.

    Partnerships & Collaborations

    We are committed to creating collaborations that maximize value for each of the partners.

    Intellectual Property

    We have established, maintained and actively pursue intellectual property protection for our technology.

    RNA Interference

    Discover how our siRNA based therapies work

    Delivery Platform

    Effective siRNA delivery to the right cells is a challenge given the complexity of the human body. Discover how we aim to address this.

    Downloads

    July 2020 corp pres pic.JPG
    • Silence Therapeutics Corporate Presentation

    Download the Corporate Presentation here

  • Pipeline
  • Focus Diseases

    To support better understanding of our focus diseases, we have developed the following ‘eBooks’ to provide an overview of their impact and current management.

    Myelodysplastic Syndromes (MDS) eBook

    General resource to improve understanding of Myelodysplastic Syndromes (MDS)

    Elevated Lipoprotein(a) eBook

    General resource to improve understanding of elevated Lipoprotein(a) (Lp(a))

    Thalassaemia eBook

    General resource to improve understanding of Thalassaemia

    Downloads

    July 2020 corp pres pic.JPG
    • Silence Therapeutics Corporate Presentation

    Download the Corporate Presentation here

  • News & media

    View our latest news, publications and videos here.

    Latest News

    View our Latest News here.

    Events

    Upcoming and past events.

    Press Coverage

    View our Press Coverage here.

    Publications

    View our Publications here.

    Media Pack

    View our Marketing Materials here.

    Downloads

    July 2020 corp pres pic.JPG
    • Silence Therapeutics Corporate Presentation

    Download the Corporate Presentation here

  • Investors
  • Careers

    We offer a vibrant culture and environment where innovation and creativity are encouraged.

    Latest job positions

    We offer a vibrant culture and environment where innovation and creativity are encouraged.

    Downloads

    July 2020 corp pres pic.JPG
    • Silence Therapeutics Corporate Presentation

    Download the Corporate Presentation here

  • Contact
Regulatory Announcements toggler
  • Results, reports & presentations
  • Shareholder information & key advisers
  • Corporate Governance
  • AIM Rule 26 checklist
  • Regulatory Announcements
  • Share price information
  • Email Alerts
  • Silence Therapeutics Overview Presentation
  • Home >
  • Regulatory Announcements

Regulatory Announcements

Subscribe for email alerts here:

  • Results, reports & presentations
  • Shareholder information & key advisers
  • Corporate Governance
  • AIM Rule 26 checklist
  • Regulatory Announcements
  • Share price information
  • Email Alerts
  • Silence Therapeutics Overview Presentation
Logo footer
  • About us
  • Our Technology
  • Pipeline
  • Focus Diseases
  • News & media
  • Investors
  • Careers
Email alerts

Corporate Headquarters

UK

72 Hammersmith Road,
London,
W14 8TH
Tel: +44 (0)20 3457 6900

Germany

Robert-Rossle-Str. 10
D-13125 Berlin
Germany
Tel: +49 30 9489 2800

US

434 West 33rd Street
Office 814
New York, NY 10001
Website by Luminous
  • Privacy and cookie notice
  • Terms of use

© Silence Therapeutics 2018. 'Silence Therapeutics', 'Silence', the Silence logo, and AtuRNAi are all trademarks of Silence Therapeutics